Skip to main content

NCT00821600 - Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia

Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL CONSTA®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
24
% Female
33.3%
% White
N/A
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
RIS-SCH-1012
Data Partner
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Collected Datasets
Annotated Case Report Form
Protocol with Amendments
Study Phase 
1

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.